Investor Presentaiton
Investor Presentation
First nine months of 2018
Slide 90
In the completed PIONEER trials between 52-80% of
patients on oral semaglutide achieved an HbA1c level <7%
In completed PIONEER trials 52-80% of patients
achieved an HbA1c level <7.0% (ADA guidance)¹
Proportion of patients
(%)
In completed PIONEER trials 28-49% of patients
achieved a weight loss of ≥ 5%¹
Proportion of patients
(%)
100%
*
80%
80%
100%
*
*
72%
*
75%
80%
69%
*
64% 63% 64%*
*
*
60%
52%
60%
44%* 47%
49%*
49%*
41%*
40%
40%
20%
20%
ناتتاتلر
*
25%
0%
0%
P1
P2
P3
P4
P5
P7
P8
P10
P1
P2
P3
P4
P5
P7
P8
P10
1 Hypothetical estimand, observed data
* Statistically significant vs comparator (PIONEER 1 vs placebo; PIONEER 2 vs empagliflozin 25 mg; PIONEER 3 vs sitagliptin 100 mg; PIONEER 4 vs Victoza® 1.8 mg; PIONEER 5 vs. placebo in T2DM and with renal
impairment; PIONEER 7 vs sitagliptin 100 mg; PIONEER 10 vs. dulaglutide in Japanese people)
Note: Results shown are: PIONEER 1 for 26 weeks with 14 mg oral semaglutide; PIONEER 2 and 4 for 52 weeks with 14 mg oral semaglutide; PIONEER 3 for 78 weeks with 14 mg oral semaglutide; PIONEER 7 for 52
weeks with a mixed dose
T2DM: Type 2 diabetes mellitus
Source: Novo Nordisk data on fileView entire presentation